Physician profile
Robert Lee Rowell
NPI 1114640505
$899.59
in general payments reported to CMS, 2019-2025
16 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $143 · 2024: $433 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.22 | 2024-2025 | Xifaxan, Trulance |
| Abbvie INC. | $123.05 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $116.25 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $79.58 | 2023-2025 | Mounjaro, Jardiance |
| Amgen INC. | $69.23 | 2024-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $68.76 | 2023-2025 | |
| Novo Nordisk INC | $55.92 | 2024-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $35.01 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $30.92 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $29.33 | 2023-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $26.01 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.83 | 2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $17.55 | 2024 | Quviviq |
| Shield Therapeutics INC | $17.19 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.70 | 2023 | Strensiq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $14.04 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.